Horses affected by EPM have increased sCD14 compared to healthy horses.

Autor: Hay AN; Department of Animal and Poultry Sciences, Virginia Tech, Blacksburg, VA, USA., Wagner B; Department of Population Medicine and Diagnostic Sciences, Cornell University, Ithaca, NY, USA., Leeth CM; Department of Animal and Poultry Sciences, Virginia Tech, Blacksburg, VA, USA., LeRoith T; Department of Biomedical Sciences and Pathobiology, Virginia- Maryland College of Veterinary Medicine, Virginia Tech, Blacksburg, VA, USA., Cecere TE; Department of Biomedical Sciences and Pathobiology, Virginia- Maryland College of Veterinary Medicine, Virginia Tech, Blacksburg, VA, USA., Lahmers KK; Department of Biomedical Sciences and Pathobiology, Virginia- Maryland College of Veterinary Medicine, Virginia Tech, Blacksburg, VA, USA., Andrews FM; Equine Health Studies Program, Department of Veterinary Clinical Sciences, School of Veterinary Medicine, Louisiana State University, Baton Rouge, LA, USA., Werre SR; Department of Population Health Sciences, Virginia- Maryland College of Veterinary Medicine, Virginia Tech, Blacksburg, VA, USA., Johnson AL; Department of Clinical Studies, University of Pennsylvania, School of Veterinary Medicine, New Bolton Center, Kennett Square, PA, USA., Clark CK; Peterson and Smith Equine Hospital, Ocala, FL, USA., Pusterla N; Department of Medicine and Epidemiology, School of Veterinary Medicine, University of California, Davis, Davis, CA, USA., Reed SM; Rood and Riddle Equine Hospital, Lexington, KY, USA., Lindsay DS; Department of Biomedical Sciences and Pathobiology, Virginia- Maryland College of Veterinary Medicine, Virginia Tech, Blacksburg, VA, USA., Taylor S; Department of Veterinary Clinical Sciences, College of Veterinary Medicine, Purdue University, West Lafayette, IN, USA., Estell KE; Department of Large Animal Clinical Sciences, Marion duPont Scott Equine Medical Center, Leesburg, VA, USA., Furr M; Department of Physiological Sciences, Center for Veterinary Health Sciences, Oklahoma State University, Stillwater, OK, USA., MacKay RJ; Department of Large Animal Clinical Sciences, University of Florida, Gainesville, FL, USA., Del Piero F; Department of Pathobiological Sciences, School of Veterinary Medicine, Louisiana State University, Baton Rouge, LA, USA., Witonsky SG; Department of Large Animal Clinical Sciences, Virginia- Maryland College of Veterinary Medicine, Virginia Tech, Blacksburg, VA, USA. Electronic address: switonsk@vt.edu.
Jazyk: angličtina
Zdroj: Veterinary immunology and immunopathology [Vet Immunol Immunopathol] 2021 Dec; Vol. 242, pp. 110338. Date of Electronic Publication: 2021 Oct 22.
DOI: 10.1016/j.vetimm.2021.110338
Abstrakt: Equine protozoal myeloencephalitis (EPM) is a debilitating neurologic disease affecting horses across the Americas. Gaps in understanding the inflammatory immune response in EPM-affected horses create difficulties with diagnosis and treatment, subsequently negatively impacting the prognosis of affected horses. The purpose of the current study was to evaluate circulating levels of the inflammatory immune marker soluble CD14 (sCD14), in horses with EPM (n = 7) and determine if they differed from healthy neurologically normal horses (n = 6). Paired sera and cerebrospinal fluid (CSF) samples were analyzed for sCD14. Inclusion criteria for EPM horses consisted of the presence of neurologic signs consistent with EPM, Sarcocystis neurona surface antigens 2, 4/3 (SnSAG 2, 4/3) ELISA serum: CSF antibody ratio ≤ 100, and a postmortem diagnosis of EPM. Control horses were neurologically normal, healthy horses with SnSAG 2, 4/3 ELISA serum: CSF antibody ratios of > 100. Serum anti-Sarcocystis neurona antibodies indicate that healthy control horses were exposed to S. neurona but resistant to developing clinical EPM. EPM cases had significantly greater concentrations of sCD14 in CSF samples compared to control horses and increased serum sCD14 concentrations. A positive correlation between sCD14 serum and CSF concentrations was observed in EPM-affected horses but not healthy horses. Soluble CD14 is an inflammatory marker, and the study results suggest it is elevated in EPM patients. When performed in conjunction with clinical evaluation and standard antibody testing, there may be potential for sCD14 to be utilized as a correlate for EPM.
(Copyright © 2021 Elsevier B.V. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: